Autopsy report · NCT06514261
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
Cause of deathOther
“Other - Pending amendment for study expansion.”
Life of this trial
- Registered 5 months before it started.
- Suspended: paused, and may or may not restart.
- 45 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 1
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine; Biospecimen Collection; Biospecimen Collection; Bone Marrow Aspiration; Buccal Swab; Iadademstat
- Participants
- 45 (planned, not actual)
- Sites
- 4
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.